Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

H-FABP as a Biomarker in Transient Ischemic Attack

  • Guamán-Pilco, Daisy R.
  • Chocano Navarro, Elvira
  • Palà, Elena
  • Lamana-Vallverdú, Marcel
  • Penalba, Anna
  • García-Rodríguez, Paula
  • Rubiera, Marta
  • Bustamante, Alejandro
  • Rovira, Alex
  • Pérez-Sánchez, Soledad
  • Azurmendi, Leire
  • Reymond, Sandrine
  • Sánchez, Jean-Charles
  • Montaner, Joan
Data access statement: Is not available to the general public., The study investigates the utility of heart fatty-acid binding protein (H-FABP) in distinguishing TIA from mimics. Data from 175 patients from the StrokeChip multicenter study was retrospectively analyzed. H-FABP level was measured using a rapid point-of-care test. Findings revealed that H-FABP levels were higher in individuals with TIA compared to mimics [3.10 ng/mL (IQR 2.13-4.78) vs. 1.70 ng/mL (IQR 1.23-2.38)] (p < 0.001). The diagnostic performance of H-FABP, assessed using the area under the curve operating characteristic curve (AUC) was 0. 83 (95% CI = 0.76-0.90) for the final model, indicating good discriminative ability. The PanelomiX determined that a combined cutoff of > 1.85 ng/ml for H-FABP, age > 42.5 years, and baseline NIHSS > 3.5 had a 100% of sensitivity and 23.30% of specificity. The study suggests that H-FABP has potential as a TIA diagnostic biomarker. The rapid application of POCT's for H-FABP measurement supports its potential use in emergency departments and primary care settings., The first study (StrokeChip) was supported by the research project IDI20130009. Development, design, and validation of a Laboratory-on-a-chip tool for the early diagnosis of stroke and its differentiation from analogous pathologies, of the Center for the Development of Industrial Technology (CDTI). The Neurovascular Research Laboratory of the Vall d'Hebron Research Institute participates in the Spanish stroke research network RICORS (RD16/0019/00021) and received funding from Instituto de Salud Carlos III (ISCIII) DTS14/00004, PI18/00804, co-financed by the European Regional Development Fund (FEDER), for stroke biomarker research. The funders had no role in the study design or conduction., Peer reviewed